Why do physicians follow a double standard when reacting to a DOJ Attack?

As a Healthtech CEO, Are You Prepared for the Day the DOJ Comes Knocking?

By Anshul Jain If you are a healthcare startup’s CEO and have never faced the government, are you truly prepared for what happens when they come knocking?

In the medical device and healthtech industry, working closely with physicians is standard practice. Innovation depends on it. Consulting agreements, speaker programs, and collaborating with top surgeons are entirely normal and legally sanctioned parts of the business.

Yet, the line between standard industry collaboration and a Department of Justice (DOJ) compliance violation can be razor-thin. You take a few doctors out to dinner to discuss a new technology. If just one of those doctors later claims the dinner was intended to influence them to use your product, your company is suddenly out of compliance.

But here is the unspoken truth of the industry: being out of compliance in a specific moment does not mean you are running an "illegal enterprise." DOJ settlements are historically common and act as the government's way to watch and enforce compliance. However, how the government, the media, and surgeons themselves treat you depends entirely on the size of your bank account.

The Goliath Pass: Medtronic, Stryker, and NuVasive

Large corporations face DOJ kickback charges constantly. To them, a DOJ investigation is just the cost of doing business.

• Medtronic has settled multiple kickback claims, including a $9.9 million settlement in 2014 for allegedly using speaking events and sporting tickets to induce physicians to use their pacemakers. In 2020, they settled for another $9.2 million over allegations involving over 130 events held at a restaurant owned by a neurosurgeon. 

• Stryker and other massive joint replacement manufacturers have historically faced major settlements over consulting fees. 

• NuVasive paid $13.5 million in 2015 to resolve allegations of paying illegal remuneration to physicians via promotional speaker fees to a society they secretly funded.

When these massive companies are charged, they have the capital to settle quickly, write the multi-million-dollar check, and move on. Surgeons routinely turn a blind eye to these DOJ attacks on legacy giants, brushing them off as corporate red tape. The media rarely names their CEOs, and the public doesn't view Medtronic or Stryker as "criminal enterprises." They are simply viewed as massive corporations paying a regulatory toll.

The David Trap: Why Small Companies Get Crucified 

When the DOJ goes after a small-to-mid-sized healthtech company, the playbook changes entirely.

Whistleblowers bring False Claims Act cases against both small and large companies indiscriminately. However, prosecutors treat small firm leadership drastically differently—targeting the C-suite and individual doctors directly, rather than leaving it as an anonymous corporate matter.

Take Life Spine, for example. In 2019, when the company faced a $5.99 million settlement over kickback allegations, the DOJ didn't just charge the corporate entity. They personally named and scrutinized CEO Michael Butler and VP Richard Greiber.

We reached out to Dr. Kingsley R. Chin—a Harvard-trained Orthopedic Spine Surgeon, founder of SpineFrontier, and CEO of KIC Ventures—who reluctantly agreed to respond to our inquiry for comment. Having endured a grueling, multi-year government investigation that ultimately concluded with the dismissal of all original Anti-Kickback and criminal charges against him, Dr. Chin highlights the stark double standard at play:

"When you are a small company and the government determines you are out of compliance they come after you personally. And if you are a big company, they come after the company."

The consequences of this double standard extend far beyond the courtroom and deep into the surgical community. While surgeons routinely ignore DOJ actions against legacy giants, they treat smaller companies with immediate hostility, jumping to assumptions of guilt.

When speaking with Dr. Chin, it became clear how deep this bias runs: despite the complete dismissal of all charges against him, many surgeons within the community continued to talk, assume guilt, and enforce these exact double standards.

The media rarely publishes an acquittal with the same fervor used to broadcast an initial charge, and the surgical community rarely updates its opinions once mindsets are set. In the court of industry opinion, the initial charge leaves a stain that facts alone struggle to wash away.

How CEOs Must Prepare for the Knock on the Door

If you are starting a healthcare company, you must operate under the assumption that you will eventually face regulatory scrutiny—and potentially be targeted personally.

When conducting research and speaking with company leaders who have weathered these storms, the consensus question remains: "If the DOJ comes, are you prepared?"

Reflecting on why founders need to understand this harsh reality early, Dr. Chin emphasized:

"I believe CEOs who are starting MedTech companies should be aware of these articles."

Here is what every Doctorpreneur and healthtech CEO must learn from this double standard:

• Understand the Nature of Compliance: Compliance isn't about whether your technology is legal or illegal; it's about strict adherence to the Anti-Kickback Statute (AKS) and Sunshine Act reporting. Every dinner, flight, and consulting hour must be logged, justified, and tied to fair market value.

• Wall Off Sales from Compliance: Ensure your compliance department operates completely independently of your sales team. A rogue sales rep promising a doctor an undocumented perk can bring federal investigators to your doorstep.

• Document the "Why": Never leave room for interpretation. When engaging a physician, the core purpose must be documented as an exchange for legitimate, tangible services (such as IP development or clinical feedback), not as an inducement to use a product.

• Mentally Prepare for Industry Stigma: If you are investigated, competitors will leverage it against you, and surgeons may rush to judgment. You must build a resilient board and executive team capable of holding the line and navigating the public relations battle.

Innovation in healthcare requires doctors and entrepreneurs to collaborate. Don't let the fear of regulatory overreach stop you from building transformative products, but never be naive enough to assume you'll receive the same grace as a MedTech giant. Build your compliance armor early, protect your executives, and take control of your narrative before someone else writes it for you.